Abiomed Stock Buy or Sell? ABMD Stocks Forecast

Market Capitalization: N/A $
EBITDA: N/A $
Price to Earnings: N/A
Quarterly Earnings Growth YOY: N/A
Quarterly Revenue Growth YOY: N/A
Trailing PE: N/A
Forward PE: N/A
Shares Outstanding: N/A






Trading Penny Stocks for Profit: Expert Insights and Practical Advice

February 22, 2024 Trading Penny Stocks for Profit: Expert Insights and Practical Advice

For aspiring traders and seasoned investors alike, the enticing appeal of penny stocks can be likened to voyaging across the vast oceans, discovering…
Getting A Kredittkort Norge Approval Isn’t Difficult

February 8, 2024 Getting A Kredittkort Norge Approval Isn’t Difficult

If you meet the conditions, you can open an account for checking in Norway. However, it will be much easier and more convenient…
How to Understand Social Security: 6 Legal & Financial Tips

January 25, 2024 How to Understand Social Security: 6 Legal & Financial Tips

Understanding social security can seem overwhelming, but it’s an important part of financial planning, particularly for retirement. The following 6 legal and financial…
Finding Energy Plans with Billig Strøm Rates

January 10, 2024 Finding Energy Plans with Billig Strøm Rates

It can be overwhelming to decide on the best plan when in a state where electricity is deregulated. The number of providers is…

Abiomed Stock Buy or Sell? ABMD Stocks Analytic Forecasts

Updated on February 27, 2024 (10:19)

Abiomed, Inc. (ABMD prediction charts) Sector: Healthcare

We present you the most up-to-date and complete review of analytical trend forecasts and views on the ABMD stock market. Experts share their opinions on what to expect from the Abiomed, Inc. stock market. How likely is the stock price to move in a bullish or bearish trend. Which should help you to make the right decision whether to Buy or Sell Abiomed stocks.

Abiomed, Inc. Stock Market Experts’ Analysis and Forecasting – Sell or Buy ABMD Shares?

The most recent analytical view which can help you to answer the worrying question: Should I Buy Stocks Now or Wait? came out under the authorship of Zach Bristow and is titled

“A Look At Abiomed Before The $380/Share Buyout From Johnson & Johnson”

is published on December 21 (2022) and has 1 likes. The review predicts Neutral market trend.

It summarize the following theses:

  • JNJ’s agreed acquisition of ABMD at $380 per share came as a surprise to many healthcare focused investors.
  • ABMD’s speed of innovation around its Impella segment have been a standout all along, as we’ve previously covered.
  • There is still some uncertainty surrounding legal proceedings from selective ABMD shareholders.
  • At this point, it’s prudent to rate ABMD a hold until further clarifications on the deal’s finalization are obtained.

The author starts his analytic review with the following:

Investment Summary Since our last publication on Abiomed, Inc. (NASDAQ:ABMD) where we had a buy thesis fully intact, there’s been several notable developments in the company’s growth route. We had previously touched on ABMD’s various strengths in return on invested capital (“ROIC”) and the speed of innovation around its core Impella heart pump segment. Turning to the present day, and the key update is Johnson & Johnson (NYSE:JNJ)’s agreed buyout of ABMD in November, for an all-cash consideration of $380 per share, valuing the company at $16.6Bn.

Zach Bristow has already 2432 followers,
which shows, he is the one who cares for his words. Zach Bristow has 413 works published.
The contributor of experts community since 2020


One more noteworthy article is written by Alpine Capital under the title

“Abiomed: Correction Offers Good Buying Opportunity”

on September 28 (2022) and has 4 likes. The expert reflects Bullish trend of the market.

Нis theses make you think about whether to add ABMD stocks to your investment portfolio or not, and helps to work out your own Abiomed stock selling strategies:

  • Abiomed’s Impella range of micro heart pumps enjoy rising demand in the marketplace.
  • The company’s OXY-1 System cardiopulmonary support device has strong growth prospect.
  • The company’s revenue will grow at a CAGR of high-single digits in the long term, which will drive the company’s share price significantly higher in the next five years.

Alpine Capital starts analysis with such words:

Abiomed’s (NASDAQ:ABMD) micro heart pumps enjoy rising demand in the cardiovascular marketplace. I expect the company’s Impella range of micro heart pumps will drive the company’s long-term revenue growth significantly, and its Impella product pipeline will support long-term revenue growth as well. Long-term growth-oriented investors can buy the company’s shares around the current price to maximize their profit.

The author declares an interesting position, and the number of his followers is 718 and it grows, but not that weighty compared to other authors.
Alpine Capital has 89 works published.
The contributor of experts community since 2018. Has published at least 89 articles.


Another analysis presented by Zach Bristow came out on August 4 (2022). Obviously, coupled with the newer reviews, this forecasting could be useful to find out the best trading strategy for ABMD stocks. It sounds like

“Abiomed: Small Premium For Access To ~11% Normalized ROIC”

Article has got 0 likes at the moment and forecasting Bullish trend of the market.

Summarizing the information presented in the review concerning the Abiomed, Inc., the expert says the following:

  • Abiomed came in with another set of robust earnings yesterday, with double-digit growth from top to bottom.
  • Earnings remain steady, however, the company exhibits the profitability features investors are paying a premium for.
  • Valuations are supporting, and we look to be paying a ~300bps premium for access to the above premia investors are searching for in FY22.
  • We remain unchanged on our previous rating of buy and valuation of $388, respectively.

And here, what comes first:

Investment summary The long-term buy thesis for Abiomed, Inc. (NASDAQ:ABMD) remains fully intact following the company’s Q1 FY23 earnings posted yesterday. After a double-digit gain from the top to bottom line, the company also saw strengths in non-GAAP reconciliations and continued to generate a substantive return on investment, generating an above-average $46 million in NOPAT from last year’s invested capital. Valuations are supportive, and we are paying ~300bps premium to obtain access to these quality factors that investors are paying a premium for in FY22. We reiterate that ABMD is a buy [since October 2020] and valuations remain unchanged at $388 per share.

Zach Bristow has already 2432 followers, which shows, he is the one who cares for his words.
The contributor of experts community since 2020. Has already 413 analytic reviews published.


The Share Price of Abiomed, Inc. (ABMD) for now

What analysts predict: $
52-week high/low: $ / $

50/200 Day Moving Average: $ / $

The average stock price over the previous 50/200 days. For Abiomed stocks, the 50-day moving average is the support level for now. For ABMD stocks, the 200-day moving average is the support level today.

See the Detailed Predictions for ABMD stock with charts and tables

Related Analysis

View all analytics

Buy or Sell ADGI shares?
January 1, 1970

Thermo Fisher’s Bright Future Makes It A Great Buy On Weakness

Buy or Sell TMO shares? Thermo Fisher’s Bright Future Makes It A Great Buy On Weakness
February 6, 2024
Drug manufacturers are facing a massive patent cliff, with over $200 billion in annual revenue at risk through 2030, meaning innovation is critical to prop up sales, and today's company focuses on that.

Revisiting Zynerba Pharmaceuticals

Buy or Sell ZYNE shares? Revisiting Zynerba Pharmaceuticals
November 11, 2021
Today, we revisit a small developmental firm called Zynerba Pharmaceuticals.

Danaher: Better Positioned For The Future

Buy or Sell DHR shares? Danaher: Better Positioned For The Future
February 3, 2024
Danaher's annual results show a decrease in sales and EBIT due to the boost in sales of the COVID-19 pandemic.